oral retatrutide Retatrutide: The New Triple-Agonist Weight Loss Treatment Lilly orforglipron oral GLP-1 phase

This is the value of medical weight loss

While preclinical and clinical studies have reported anti-metabolic and anti-inflammatory benefits with a favourable safety profile, further evidence from long-term and large-scale trials is necessary to guide clinicians in real-life scenarios

Oral GLP-1 programs remained minimal until the late 2000s, then began rising meaningfully post-2018with the most visible step-up in the last few years: 10 oral programs in 2022, and 11 each in 2024 and 2025

Morgan Stanley Research analysts estimate that 24m people, or 7% of the US population, will be on the weight-loss drugs by 2035

Forma parte de las seales de saciedad que permiten mantener un equilibrio en la ingesta de energa, resume Inka Miambres, miembro del comit gestor del rea de Obesidad de la Sociedad Espaola de Endocrinologa y Nutricin (SEEN)